The score is primarily weighed down by weak financial performance (zero/very low revenue, recurring losses, and mostly negative operating/free cash flow) and bearish technical signals (below key moving averages with negative MACD). Valuation does not provide meaningful support because the company is loss-making and there is no dividend yield data.
Positive Factors
Moderate leverage and stable equity
A moderate debt-to-equity (~0.9x) and relatively stable equity provide a structural buffer versus highly leveraged peers. This balance-sheet posture can buy management time to restructure operations or raise incremental capital, preserving optionality over the next 2–6 months.
EBITDA sometimes positive
Intermittent positive EBITDA implies the underlying operations can generate cash before capex and financing. That operating profitability pocket can support working-capital needs or form the base for margin recovery if revenues stabilize or cost rationalization is executed.
Lean workforce (low fixed cost base)
A small employee base suggests a lean cost structure and operational agility. Lower structural fixed payroll costs make it easier to reduce cash burn quickly, reallocate resources, or pivot product/service focus without large labor frictions, supporting near-term survivability.
Negative Factors
Revenue collapsed to zero in FY2025
A fall to zero reported annual revenue is a structural red flag: it signals loss of core sales or customers and breaks the revenue engine. Absent a clear business restart, recovery requires rebuilding demand or new product/market entry, a multi-month structural undertaking.
Persistent negative operating and free cash flow
Repeated negative operating and free cash flows indicate ongoing cash burn and limited internal funding capacity. Over a multi-month horizon this constrains investment, forces reliance on external financing, and raises solvency risk if cash sources are not secured or expenses not materially reduced.
Recurring net losses and negative returns
Sustained net losses and persistently negative ROE erode shareholder equity and undermine reinvestment potential. This structural profitability gap reduces ability to attract new capital, limits strategic initiatives, and heightens risk of long-term value destruction absent a profitable turnaround.
Seya Industries Ltd. (SEYAIND) vs. iShares MSCI India ETF (INDA)
Market Cap
₹261.72M
Dividend YieldN/A
Average Volume (3M)2.13K
Price to Earnings (P/E)―
Beta (1Y)0.63
Revenue GrowthN/A
EPS GrowthN/A
CountryIN
Employees28
SectorBasic Materials
Sector Strength58
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)-0.23
Shares Outstanding26,570,540
10 Day Avg. Volume0
30 Day Avg. Volume2,135
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)0.05
Price to Sales (P/S)0.00
P/FCF Ratio-2.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Seya Industries Ltd. Business Overview & Revenue Model
Company DescriptionSeya Industries Limited manufactures and sells specialty chemicals in India and internationally. The company's products include pigment intermediates, chloro benzenes, nitro chloro benzenes, and acids. It offers its products for use in computer printing inks, pigments and paints, pharmaceuticals, personal and health care products, agrochemicals, insecticides/pesticides, organic chemical intermediates, rubber chemicals, textile dyes, thermic fluids, etc. The company was formerly known as Sriman Organic Chemical Industries Limited and changed its name to Seya Industries Limited in June 2011. Seya Industries Limited was incorporated in 1990 and is based in Mumbai, India.
How the Company Makes Money
Seya Industries Ltd. Financial Statement Overview
Summary
Financials indicate significant stress: revenue contracted sharply and fell to zero in FY2025, with recurring net losses and mostly negative operating profit. Cash flow is generally weak with negative operating and free cash flow in most years, implying ongoing cash burn. The balance sheet is a relative support with moderate leverage and stable equity, but persistently negative returns increase risk if weakness continues.
Income Statement
14
Very Negative
Operating performance is weak and volatile. Revenue has contracted sharply over the period and fell to zero in FY2025 (annual), following already low sales levels in FY2024. Profitability remains negative with recurring net losses (including a very large loss in FY2021) and negative operating profit in most years. A key positive is that EBITDA is sometimes positive despite losses, but the overall earnings quality and consistency are poor.
Balance Sheet
42
Neutral
Leverage appears moderate for a specialty chemicals profile, with debt-to-equity hovering around ~0.9x across years, and equity remaining sizable and relatively stable. However, returns are persistently negative (return on equity is below zero each year provided), indicating the balance sheet is not generating adequate shareholder value and could face pressure if losses and weak revenues persist.
Cash Flow
18
Very Negative
Cash generation is inconsistent and generally weak. Operating cash flow is negative in most years (including FY2023–FY2025), with only FY2022 showing a meaningful positive inflow. Free cash flow is also mostly negative (including a large outflow in FY2020), suggesting ongoing cash burn and limited internally funded flexibility.
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Feb 27, 2026